BELGRADE, Mont., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the issuance of new convertible promissory notes on January 17, 2017 (the “New Notes”) to ROS Acquisition Offshore LP (“ROS”) and OrbiMed Royalty Opportunities II, LP (“OrbiMed”) for the following interest pay…
BELGRADE, Mont., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the closing of a registered direct offering conducted without an underwriter or placement agent (the "Offering"). The Offering closed on January 17, 2017 and was with certain holders of its convertible promissory notes (“…
BELGRADE, Mont., Jan. 13, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced that it has entered into an agreement with certain holders of its convertible promissory notes (“Indenture Notes”) to purchase shares of Xtant's common stock in a registered direct offering conducted without an underwriter or p…
January 2, 2017: XTANT Medical proudly sponsored the Donate Life Float, themed “Teammates in Life”, in the 2017 Tournament of Roses. Our sponsorship provides an opportunity to give back to our donor families, to support and give thanks to our recovery partners and Donate Life America, and is part of a national effort to share the life-giving message that organ, eye, and tissue donation saves and heals lives.
The 2017 Pasadena Tournament of Roses theme,…Belgrade, MT, November 22, 2016 – Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Xsert Lumbar Expandable Interbody System.
The Xsert System is an all titanium expandable interbody device that expands in-situ. It is available in various sizes and lordotic angulations to fit the most complex anatom…BELGRADE, Mont., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today the closing of its rights offering (the "Offering") of units at a subscription price of $0.75 per unit, for aggregate gross proceeds to the Company of approximately $3.8 million.
Pursuant to the Rights Offering, Xtant sold an aggr…BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that the subscription period for its previously announced rights offering (the "Offering") of units at a subscription price of $0.75 per unit expired on November 14, 2016, and these rights are no longer exercisable.
Based on the r…Belgrade, MT, November 15, 2016 – Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Irix-C cervical cage for use with autograft and/or allograft and the expansion of the range of levels allowable from C3-T1 to C2-T1. Previously the device was cleared only for use with autogenous bone graft. This furthers…
Xtant Medical will be exhibiting at the North American Spine Society (NASS) in Boston, Massachusetts, October 26-28, 2016. Come visit us at Booth #1202 in the Boston Convention & Exhibition Center. Xtant Medical will also have a Product Demonstration on Thursday, October 27th, 11:00am-1:00pm. For more information on the demonstration, contact professionaleducation@xtantmedical.com.